Human Papillomavirus (HPV) Vaccines: Limited Cross‐Protection against Additional HPV Types

  • Herrero R
  • 53

    Readers

    Mendeley users who have this article in their library.
  • 67

    Citations

    Citations of this article.

Abstract

Approximately 15 different human papillomavirus (HPV) types from 5 species (A5, A6, A7, A9, and A11) may cause cervical cancer. They are grouped according to phylogenetic relatedness, which also correlates with carcinogenicity [1]. The majority of HPV types associated with human cancers are from species A7 (HPV-18, -39, -45, -59, and -68) and A9 (HPV-16, -31, -33, -35, -52, and -58). Given their similarity, phylogenetically related HPV types share capsid epitopes that can elicit a cross-reactive immune response, and, although serological cross-reactivity has been demonstrated in epidemiological studies of naturally infected women with and without cervical cancer [2, 3], vaccine-elicited neutralizing antibodies were expected to be largely type specific

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Rolando Herrero

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free